
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
FDA has issued a list of planned draft and final guidance documents for release throughout 2012.
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are about 50 such
In biopharmaceutics and biosimilarity:
In combination products:
In CGMPs and compliance:
In labeling, packaging, and supply chain:
In regulatory filings (electronic):






